JP2021512637A5 - - Google Patents

Info

Publication number
JP2021512637A5
JP2021512637A5 JP2020543065A JP2020543065A JP2021512637A5 JP 2021512637 A5 JP2021512637 A5 JP 2021512637A5 JP 2020543065 A JP2020543065 A JP 2020543065A JP 2020543065 A JP2020543065 A JP 2020543065A JP 2021512637 A5 JP2021512637 A5 JP 2021512637A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
chain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512637A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017708 external-priority patent/WO2019157524A1/en
Publication of JP2021512637A publication Critical patent/JP2021512637A/ja
Publication of JP2021512637A5 publication Critical patent/JP2021512637A5/ja
Priority to JP2023126157A priority Critical patent/JP2023133505A/ja
Pending legal-status Critical Current

Links

JP2020543065A 2018-02-12 2019-02-12 サイクリンa1特異的t細胞受容体およびその使用 Pending JP2021512637A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023126157A JP2023133505A (ja) 2018-02-12 2023-08-02 サイクリンa1特異的t細胞受容体およびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862629648P 2018-02-12 2018-02-12
US62/629,648 2018-02-12
US201862630198P 2018-02-13 2018-02-13
US62/630,198 2018-02-13
US201862667207P 2018-05-04 2018-05-04
US62/667,207 2018-05-04
PCT/US2019/017708 WO2019157524A1 (en) 2018-02-12 2019-02-12 Cyclin a1 specific t cell receptors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023126157A Division JP2023133505A (ja) 2018-02-12 2023-08-02 サイクリンa1特異的t細胞受容体およびその使用

Publications (2)

Publication Number Publication Date
JP2021512637A JP2021512637A (ja) 2021-05-20
JP2021512637A5 true JP2021512637A5 (cg-RX-API-DMAC7.html) 2022-02-22

Family

ID=65767286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020543065A Pending JP2021512637A (ja) 2018-02-12 2019-02-12 サイクリンa1特異的t細胞受容体およびその使用
JP2023126157A Pending JP2023133505A (ja) 2018-02-12 2023-08-02 サイクリンa1特異的t細胞受容体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023126157A Pending JP2023133505A (ja) 2018-02-12 2023-08-02 サイクリンa1特異的t細胞受容体およびその使用

Country Status (11)

Country Link
US (1) US12570712B2 (cg-RX-API-DMAC7.html)
EP (1) EP3752525A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021512637A (cg-RX-API-DMAC7.html)
CN (1) CN112004825A (cg-RX-API-DMAC7.html)
AU (1) AU2019218397A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016330A8 (cg-RX-API-DMAC7.html)
CA (1) CA3090700A1 (cg-RX-API-DMAC7.html)
IL (1) IL276556A (cg-RX-API-DMAC7.html)
MX (1) MX2020008403A (cg-RX-API-DMAC7.html)
SG (1) SG11202007660UA (cg-RX-API-DMAC7.html)
WO (1) WO2019157524A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120605327A (zh) * 2019-11-06 2025-09-09 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术(广东)有限公司 一种识别afp的t细胞受体
EP4168451A2 (en) 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰(北京)生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
CN114057864B (zh) * 2020-07-30 2023-12-15 香雪生命科学技术(广东)有限公司 一种识别afp的高亲和力tcr
WO2022156687A1 (en) * 2021-01-19 2022-07-28 Wuxi Biologics (Shanghai) Co., Ltd. Polypeptide complexes with improved stability and expression
KR20240007162A (ko) * 2021-04-14 2024-01-16 티스캔 테라퓨틱스, 인크. Magec2 면역원성 펩티드, magec2 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도
WO2024263821A2 (en) * 2023-06-20 2024-12-26 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US20020053092A1 (en) 1997-11-14 2002-05-02 Readhead Carol W. Nucleic acid constructs containing a cyclin A1 promoter, and kit
US6461813B2 (en) 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2009040789A2 (en) 2007-09-24 2009-04-02 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
WO2013071154A1 (en) * 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
WO2016090177A1 (en) 2014-12-03 2016-06-09 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201516272D0 (en) * 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
AU2022231657B2 (en) Compositions and Methods for Treating Cancer
Schooten et al. MAGE-A antigens as targets for cancer immunotherapy
Li et al. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
JP6974311B2 (ja) 新規pd−1免疫調節剤
JP2022116230A (ja) 免疫療法用改変細胞
WO2019005641A1 (en) GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
JP2017531687A5 (cg-RX-API-DMAC7.html)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
CA3119644A1 (en) Chimeric antigen receptor factories and methods of use thereof
JP2022528030A5 (cg-RX-API-DMAC7.html)
JP2020533962A5 (cg-RX-API-DMAC7.html)
Yang et al. Opportunities and challenges for antibodies against intracellular antigens
CN113272016A (zh) 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法
EP3710472A1 (en) Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof
JP2022547809A5 (cg-RX-API-DMAC7.html)
JP2024541175A (ja) Herv-k抗体治療法
Hanagiri et al. Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes
TWI805792B (zh) 抗腫瘤劑及其評估方法
Sallman et al. Is disease-specific immunotherapy a potential reality for MDS?
US20240148867A1 (en) Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
Subklewe Current status of immunotherapy in acute myeloid leukemia
Baybutt CD8ɑ Structural Domains Enhance GUCY2C CAR-T Cell Efficacy
HK40097672A (en) Guidance and navigation control proteins and method of making and using thereof
HK40097671A (en) Guidance and navigation control proteins and method of making and using thereof